§ Claim under review · Health
"New-generation treatments such as Lecanemab and Donanemab have, for the first time, shown the ability to slow down brain degeneration in the early stages of Alzheimer's disease" SECONDARY CLAIMS IDENTIFIED (in the post's image text): A. "Alzheimer's disease will be completely eradicated within the next five years." B. "Several of these vaccines have already entered human clinical trials, and early results suggest they may help the brain resist the progression of memory loss." C. Implied: supplements can prevent Alzheimer's and dementia (engagement bait, no source offered).
Verdict
Partially accurate but misleading
Confidence
HighSummary
This post takes a real scientific development and overstates it. Lecanemab and donanemab are genuine drugs that passed large phase 3 trials and slowed the rate of cognitive decline in people with early Alzheimer's, and lecanemab has full FDA approval. But the trials measured decline on memory and function rating scales, not "brain degeneration," and that distinction matters: pooled MRI data across anti-amyloid drug trials actually shows faster brain volume loss on these drugs, not slower. The real benefit is modest, roughly a 0.45-point difference on an 18-point scale over 18 months, and experts still disagree about how much that means for patients. The drugs also carry a risk of brain swelling and bleeding, which is why the FDA issued the MRI monitoring notice that the post links to but never mentions. The separate claim that Alzheimer's "will be completely eradicated within the next five years" has no identifiable source and is not supported by any evidence found. The vaccine research is real but very early, with one trial explicitly stating it was not designed to prove cognitive benefit and another testing only healthy volunteers without Alzheimer's. Finally, none of the cited sources say anything about supplements, which is what the post is actually asking you to sign up for.
The readings
key figures from the evidenceClarity AD CDR-SB difference, lecanemab vs placebo at 18 months
TRAILBLAZER-ALZ 2 trial completers (donanemab)
Why this verdict
Evidence
The underlying drugs and trials are real, and the direction of the finding is real. In Clarity AD, mean change in CDR-SB from baseline at 18 months as the primary endpoint was 1.21 for lecanemab and 1.66 for placebo, a difference of -0.45 (95% CI: -0.67, -0.23; P=0.00005), representing a 27% slowing of decline . TRAILBLAZER-ALZ 2 was an 18-month phase 3 trial completed by 1736 participants across 277 sites, comparing donanemab to placebo in patients aged 60 to 85 with early-stage Alzheimer's with mild cognitive impairment or mild dementia , and donanemab significantly slowed the rate of cognitive decline compared to placebo, with the effect most pronounced in those with lower levels of cerebral tau on PET imaging; the primary outcome was change in the integrated Alzheimer's Disease Rating Scale (iADRS) from baseline at 76 weeks . Lecanemab has received traditional FDA approval to treat early Alzheimer's disease, including people with mild cognitive impairment or mild dementia due to Alzheimer's with confirmed amyloid pathology .
However, the specific wording of the claim, "slow down brain degeneration," does not match what the trials measured, and on the standard imaging measure of neurodegeneration the evidence points the opposite way. The approved agents, lecanemab and donanemab, slow cognitive deterioration, although they showed modest effect sizes in clinical trials lasting 18 months, and amyloid-related imaging abnormalities (ARIA) were a common side effect. MRI-detectable brain volume changes, reflecting neurodegeneration, offer a surrogate indicator of Alzheimer's progression, and paradoxically anti-amyloid therapies cause accelerated volumetric change, particularly in people who develop ARIA.
A meta-analysis found that pooled random effects showed these therapies significantly accelerated volumetric changes to the ventricles (mean difference +0.9 ml; 95% CI, 0.3 to 1.5), whole brain (mean difference -1.4 ml; 95% CI, -2.4 to -0.4), and hippocampus (-14.5 μL; 95% CI, -24.9 to -4.1) . Exaggerated brain atrophy in the form of enlarged ventricular CSF volume or hippocampal and whole brain shrinkage has been observed for anti-amyloid therapies including lecanemab, donanemab and aducanumab .
The picture is not uniform. One analysis notes there is no consistent evidence for excess hippocampal volume loss across anti-amyloid immunotherapies, and phase 3 trials of lecanemab and donanemab demonstrated less hippocampal loss . The honest summary is that these drugs demonstrably slow measured clinical decline, while their effect on structural brain degeneration is contested and in important respects unfavorable.
Findings
✓ What's accurate 6
- Lecanemab and donanemab exist, are anti-amyloid monoclonal antibodies, and have completed large phase 3 randomized controlled trials in early-stage Alzheimer's.
- Both trials met their primary clinical endpoints with statistically significant results favoring the drug.
- Lecanemab holds traditional FDA approval for early Alzheimer's.
- The characterization of these as a meaningful first is defensible in the narrow sense that they are the first anti-amyloid antibodies to show statistically significant slowing of clinical decline in confirmatory phase 3 trials and win traditional FDA approval on that basis.
- Alzheimer's vaccines are genuinely in human trials, including ABvac40 (phase 2) and AV-1959R (phase 1), and AV-1959R is a real product identifier, not an invented label.
- The FDA links in the caption are to real FDA pages.
? What's uncertain 5
- Whether "for the first time" is strictly correct is debatable rather than resolvable. Aducanumab received an earlier accelerated approval on contested data, and in its phase 3 program a planned futility analysis concluded treatment was not beneficial and the trials were terminated, after which the EMERGE trial met its primary outcome on CDR-SB while ENGAGE did not. Reasonable experts place the "first" marker differently.
- I could not retrieve the full text of the Cochrane review directly, only expert commentary on it, so I characterize its conclusion with that limitation.
- Long-term outcomes beyond 18 months remain unsettled. Open-label extension data out to 48 months exists but I did not retrieve its full results.
- I could not identify any named expert or institution behind the "eradicated within five years" prediction. I found no trace of such a claim in any retrieved source. Absence of evidence here is strong but not absolute.
- The clinical significance of the accelerated brain volume loss is itself an open research question rather than a settled harm.
Sources
9 of 9 linked to recordsEisai/Biogen full Clarity AD phase 3 results (CTAD presentation)
"Missing tissue, missing data: Resolving brain volume loss caused by anti-amyloid therapies," PLOS Medicine
Meta-analysis of volumetric change across anti-amyloid trials (reported via NeurologyLive)
"Evaluating clinical meaningfulness of anti-β-amyloid therapies amidst ARIA concern," Brain Communications (Oxford)
ABvac40 phase 2 trial, Alzheimer's & Dementia (the PubMed link the post itself cites, PMID 41058018)
ClinicalTrials.gov NCT06831812, AV-1959R phase 1 (the vial pictured in the post)
Alzheimer's Association, lecanemab approval status
UK Dementia Research Institute response to Cochrane review of anti-amyloid antibodies
Araclon Biotech press release on ABvac40 CTAD results